Logo image of BIOA

BIOAGE LABS INC (BIOA) Stock Fundamental Analysis

NASDAQ:BIOA - Nasdaq - US09077V1008 - Currency: USD

4.5  +0.1 (+2.27%)

After market: 4.5 0 (0%)

Fundamental Rating

2

Taking everything into account, BIOA scores 2 out of 10 in our fundamental rating. BIOA was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of BIOA is average, but there are quite some concerns on its profitability. BIOA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIOA has reported negative net income.
BIOA Yearly Net Income VS EBIT VS OCF VS FCFBIOA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -20M -40M -60M

1.2 Ratios

BIOA has a better Return On Assets (-18.93%) than 63.78% of its industry peers.
With a decent Return On Equity value of -20.35%, BIOA is doing good in the industry, outperforming 71.35% of the companies in the same industry.
Industry RankSector Rank
ROA -18.93%
ROE -20.35%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOA Yearly ROA, ROE, ROICBIOA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 0 -200 -400

1.3 Margins

BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOA Yearly Profit, Operating, Gross MarginsBIOA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, BIOA has about the same amount of shares outstanding.
The debt/assets ratio for BIOA is higher compared to a year ago.
BIOA Yearly Shares OutstandingBIOA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M
BIOA Yearly Total Debt VS Total AssetsBIOA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 3.79 indicates that BIOA is not in any danger for bankruptcy at the moment.
BIOA has a better Altman-Z score (3.79) than 75.68% of its industry peers.
BIOA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BIOA has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.79
ROIC/WACCN/A
WACCN/A
BIOA Yearly LT Debt VS Equity VS FCFBIOA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 20M -20M -40M

2.3 Liquidity

BIOA has a Current Ratio of 17.63. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
BIOA has a Current ratio of 17.63. This is amongst the best in the industry. BIOA outperforms 90.27% of its industry peers.
BIOA has a Quick Ratio of 17.63. This indicates that BIOA is financially healthy and has no problem in meeting its short term obligations.
BIOA has a better Quick ratio (17.63) than 90.27% of its industry peers.
Industry RankSector Rank
Current Ratio 17.63
Quick Ratio 17.63
BIOA Yearly Current Assets VS Current LiabilitesBIOA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BIOA have decreased strongly by -60.75% in the last year.
EPS 1Y (TTM)-60.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIOA will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.55% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-98.45%
EPS Next 2Y-28.01%
EPS Next 3Y-17.55%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOA Yearly Revenue VS EstimatesBIOA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026
BIOA Yearly EPS VS EstimatesBIOA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOA Price Earnings VS Forward Price EarningsBIOA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOA Per share dataBIOA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as BIOA's earnings are expected to decrease with -17.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.01%
EPS Next 3Y-17.55%

More info and screens

0

5. Dividend

5.1 Amount

BIOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAGE LABS INC

NASDAQ:BIOA (2/21/2025, 8:03:30 PM)

After market: 4.5 0 (0%)

4.5

+0.1 (+2.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners65.17%
Inst Owner Change-99.88%
Ins Owners3.63%
Ins Owner Change0%
Market Cap161.32M
Analysts45
Price Target6.46 (43.56%)
Short Float %5.29%
Short Ratio2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-85.04%
EPS NQ rev (1m)-13.33%
EPS NQ rev (3m)-6.45%
EPS NY rev (1m)-6.52%
EPS NY rev (3m)-24.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.51
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.75
TBVpS8.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.93%
ROE -20.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.63
Quick Ratio 17.63
Altman-Z 3.79
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-98.45%
EPS Next 2Y-28.01%
EPS Next 3Y-17.55%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-64.51%
EBIT Next 3Y-39.5%
EBIT Next 5YN/A
FCF growth 1Y-3.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.26%
OCF growth 3YN/A
OCF growth 5YN/A